Gossamer Bio Inc (GOSS) Stock Price, Quote & News

Company Profile

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercia...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 684 1300

Website: www.gossamerbio.com

Address:

3115 Merryfield Row, Suite 120, San Diego, United States

ynnejkrap Oct. 10 at 10:42 PM

$GOSS hi just seeing this company. What’s the potential upswing given the phase II results ?

1 · Reply

boomupwego Oct. 10 at 8:28 PM

$GOSS one last comment before the weekend. For those who haven’t caught on yet, the stock shot up so quickly for the same reason it’s dropping now: market makers. They ran it up to trap retail, and they have been dropping it to collect the money on their short positions. Then when it gets to a point they like they’re going to load up on a bunch of cheap shares because they know the potential this has. Bunch of rich assholes sitting around laughing right now because we make it too easy for them. Know what you hold or hit the road.

1 · Reply

mmtiddy Oct. 10 at 8:08 PM

$GOSS Notice how any time it tried breaking a resistance a huge red candle happened the next day lol No one wants to hold this sadly

1 · Reply

mmtiddy Oct. 10 at 8:06 PM

$GOSS What a healthy monthly graph

1 · Reply

King_of_Bio Oct. 10 at 8:03 PM

$GOSS Rebound starts next week - if you selling for a loss, you WILL regret it later.

1 · Reply

Upticksdaily Oct. 10 at 8:02 PM

$GOSS Added at $2.25 🫤, although it’s tough to buy on the way down, I think in the next 3 months I’ll be happy with the extra shares I grabbed today, good luck to all who are holding through this downtrend

0 · Reply

mmtiddy Oct. 10 at 7:59 PM

$GOSS People who bought at $3

0 · Reply

boomupwego Oct. 10 at 7:55 PM

$GOSS Shorts made a killing today and didn’t even have to try. For the life of me I will never understand why people panic sell. Nothing like locking in losses to round out a portfolio.

0 · Reply

taylorswifit Oct. 10 at 7:40 PM

$GOSS piece of junk bro

1 · Reply

Abracadabrah Oct. 10 at 7:04 PM

$GOSS $2.20 then we rise. Almost there.

0 · Reply

Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital

Sep 25, 2025, 7:31 AM EDT - 15 days ago

Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension

Sep 22, 2025, 7:31 AM EDT - 18 days ago

Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025

Sep 10, 2025, 5:30 PM EDT - 4 weeks ago

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sep 9, 2025, 9:50 AM EDT - 4 weeks ago

Gossamer Bio: Bullish Ahead Of Seralutinib's Phase 3 Readout

Aug 29, 2025, 7:31 AM EDT - 6 weeks ago

Gossamer Bio to Present at Upcoming Investor Conferences

Aug 5, 2025, 4:01 PM EDT - 2 months ago

Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update

Jun 16, 2025, 7:31 AM EDT - 4 months ago

Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH

May 15, 2025, 9:30 PM EDT - 5 months ago

Gossamer Bio, Inc. (GOSS) Q1 2025 Earnings Conference Call Transcript

May 15, 2025, 4:01 PM EDT - 5 months ago

Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study

May 12, 2025, 4:01 PM EDT - 5 months ago

Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025

May 7, 2025, 4:01 PM EDT - 5 months ago

Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference

Mar 13, 2025, 4:01 PM EDT - 7 months ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Feb 13, 2025, 7:42 PM EST - 8 months ago

Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD

Feb 3, 2025, 7:01 AM EST - 8 months ago

Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Jan 28, 2025, 7:01 AM EST - 9 months ago

Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Nov 7, 2024, 4:03 PM EST - 1 year ago

Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update

Sep 10, 2024, 1:25 AM EDT - 1 year ago

Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss

Aug 26, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024

Aug 20, 2024, 7:00 AM EDT - 1 year ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA CVKD ELUT EUDA GDTC GOVX IMRN

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

Jun 25, 2024, 2:39 PM EDT - 1 year ago

Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says

May 14, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

May 7, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024, 7:46 AM EDT - 1 year ago

Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment

May 6, 2024, 7:30 AM EDT - 1 year ago

Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications

May 3, 2024, 8:02 AM EDT - 1 year ago

Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine

Mar 12, 2024, 7:31 AM EDT - 1 year ago

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D.

Mar 5, 2024, 7:31 AM EST - 1 year ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Dec 13, 2023, 4:01 PM EST - 1 year ago

Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023

Dec 5, 2023, 7:01 AM EST - 2 years ago

Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

Nov 29, 2023, 7:01 AM EST - 2 years ago

Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors

Nov 9, 2023, 7:31 AM EST - 2 years ago

Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update

Oct 3, 2023, 4:08 PM EDT - 2 years ago

Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs

Sep 7, 2023, 7:44 AM EDT - 2 years ago

Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023

Aug 8, 2023, 4:01 PM EDT - 2 years ago

Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update

Jul 24, 2023, 4:16 PM EDT - 2 years ago

Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results

Jul 20, 2023, 7:56 AM EDT - 2 years ago

Gossamer Bio Announces $212 Million Private Placement Financing

May 18, 2023, 7:05 AM EDT - 2 years ago

Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference

May 9, 2023, 4:01 PM EDT - 2 years ago

Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update

Apr 2, 2023, 4:12 AM EDT - 2 years ago

Gossamer Bio: Merck's STELLAR Data Impressive, But Game Not Over For Seralutinib

Mar 17, 2023, 7:31 AM EDT - 2 years ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update

Jan 30, 2023, 4:48 AM EST - 2 years ago

Gossamer: Disappointing Phase 2 Results But Too Cheap To Ignore

Dec 8, 2022, 1:27 PM EST - 3 years ago

Gossamer Bio: Buying The Savage Dip After A Trial 'Win' May Be Unwise

Dec 6, 2022, 8:19 AM EST - 3 years ago

Gossamer Bio's stock falls 64% on findings for Phase 2 study for hypertension drug

Dec 6, 2022, 7:15 AM EST - 3 years ago

Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH

Nov 3, 2022, 4:01 PM EDT - 3 years ago

Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update

Oct 20, 2022, 3:35 PM EDT - 3 years ago

This little-known biopharma stock could rally 70%: Goldman Sachs

ynnejkrap Oct. 10 at 10:42 PM

$GOSS hi just seeing this company. What’s the potential upswing given the phase II results ?

1 · Reply

boomupwego Oct. 10 at 8:28 PM

1 · Reply

mmtiddy Oct. 10 at 8:08 PM

$GOSS Notice how any time it tried breaking a resistance a huge red candle happened the next day lol No one wants to hold this sadly

1 · Reply

mmtiddy Oct. 10 at 8:06 PM

$GOSS What a healthy monthly graph

1 · Reply

King_of_Bio Oct. 10 at 8:03 PM

$GOSS Rebound starts next week - if you selling for a loss, you WILL regret it later.

1 · Reply

Upticksdaily Oct. 10 at 8:02 PM

0 · Reply

mmtiddy Oct. 10 at 7:59 PM

$GOSS People who bought at $3

0 · Reply

boomupwego Oct. 10 at 7:55 PM

$GOSS Shorts made a killing today and didn’t even have to try. For the life of me I will never understand why people panic sell. Nothing like locking in losses to round out a portfolio.

0 · Reply

taylorswifit Oct. 10 at 7:40 PM

$GOSS piece of junk bro

1 · Reply

Abracadabrah Oct. 10 at 7:04 PM

$GOSS $2.20 then we rise. Almost there.

0 · Reply

BB_king Oct. 10 at 6:11 PM

$GOSS adding here

0 · Reply

boomupwego Oct. 10 at 5:18 PM

$GOSS Good news is SSR is now active rest of day and Monday. Silver linings in every dark cloud.

0 · Reply

mmtiddy Oct. 10 at 5:17 PM

$GOSS $XBI has been up this month and $GOSS taking the L

0 · Reply

StockScubaDiver Oct. 10 at 5:14 PM

$GOSS what’s insane will be the 🚀

0 · Reply

heyupikachu1821 Oct. 10 at 4:40 PM

$GOSS more like GROSS, amiright? I’ve now averaged down 4 times on top of my original purchase. and while I get that the entire market dropped on Trump’s stupid trade wars, GOSS dropped 9%. that’s insane

2 · Reply

boomupwego Oct. 10 at 4:09 PM

$GOSS Will be amazed if we don’t see a large push in the next hour to clear out a lot of the 2.28-2.30 stop losses. 100k+ dumps have been like clockwork.

0 · Reply

Abracadabrah Oct. 10 at 3:07 PM

$GOSS Anything under $2.20 and I am loading up.

0 · Reply

mmtiddy Oct. 10 at 2:45 PM

$GOSS Thank god I left this stock

1 · Reply

Abracadabrah Oct. 10 at 3:41 AM

$GOSS $2.70 1 hour candle fill is my entry. I still think we go down to $2.20. Bring that 20 RSI to me. Waiting patiently.

0 · Reply

Finnish_boy Oct. 9 at 8:43 PM

$GOSS

1 · Reply

boomupwego Oct. 9 at 7:40 PM

$GOSS Not sold on the direction this will head in the short term. Options are currently partially responsible for the price deviation but if the shorts hit a wall in the last week, they may be “allowing” the run up to give them room to drop it again. Like to see 2.70 again before deciding if the uptick is legit.

1 · Reply

Finnish_boy Oct. 9 at 6:38 PM

$GOSS Bought more at $2.55.. amazing r/r

1 · Reply

Market Cap	582.10M
Revenue (ttm)	114.70M
Net Income (ttm)	-56.53M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-49.29%
Debt to Equity Ratio	0.00

Volume	4,325,600
Avg Vol	3,939,014
Day's Range	N/A - N/A
Shares Out	227.38M
Stochastic %K	11%
Beta	1.94
Analysts	Strong Sell
Price Target	$9.25